Navigation Links
VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
Date:5/5/2010

BEDFORD, Mass., May 5 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new VivoTag® 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.  

The new VivoTag 645 represents VisEn's first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas.  The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.  

"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas."

The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas.  The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn's fluorescence tomography FMT™ imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, GastroSense™, ReninSenseTM, Annexin-VivoTM, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent
2. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
3. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
4. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
5. VisEn Medical Raises $7 Million in Series B Financing
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. BellBrook Labs Launches Compound Profiling Services with High Content 3D Invasion Assay
8. Ansell Launches Worldss First Antimicrobial Surgical Glove
9. ChromaDex Launches pTeroPure Pterostilbene
10. Vermont Launches Renewable Energy Atlas
11. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, ... trait and seed provider, and Arcadia (Arcadia ... that develops and commercializes agricultural productivity traits and nutritional products, today ... corn biotechnology product developed in China to ... regulatory trials. ...
(Date:2/22/2017)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results ... 2016. "Our annual 2016 financial results ... billion and earnings exceeded $700 million," said Martine ... Officer. "These financial results strengthen our ability to ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and biotech research and development (R&D), today announced the establishment of Genedata Limited ... Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the ...
(Date:2/21/2017)... ... , ... Creation Technologies, a private company and 25-year leader ... , today announced it has received the ‘Highest Overall Customer Rating’ Service Excellence ... of electronics manufacturing services (EMS) providers with annual revenues over $500 million. The ...
Breaking Biology Technology:
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
Breaking Biology News(10 mins):